The G glycoprotein of respiratory syncytial virus depresses respiratory rates through the CX3C motif and substance P.
about
Respiratory Syncytial Virus (RSV) Modulation at the Virus-Host Interface Affects Immune Outcome and Disease PathogenesisModulation of host adaptive immunity by hRSV proteinsSevere respiratory syncytial virus bronchiolitis in infants is associated with reduced airway interferon gamma and substance P.Vaccination to induce antibodies blocking the CX3C-CX3CR1 interaction of respiratory syncytial virus G protein reduces pulmonary inflammation and virus replication in mice.Effects of anti-g and anti-f antibodies on airway function after respiratory syncytial virus infectionProphylactic treatment with a G glycoprotein monoclonal antibody reduces pulmonary inflammation in respiratory syncytial virus (RSV)-challenged naive and formalin-inactivated RSV-immunized BALB/c mice.The respiratory syncytial virus G protein conserved domain induces a persistent and protective antibody response in rodentsProphylaxis with a respiratory syncytial virus (RSV) anti-G protein monoclonal antibody shifts the adaptive immune response to RSV rA2-line19F infection from Th2 to Th1 in BALB/c mice.Assembly and immunological properties of Newcastle disease virus-like particles containing the respiratory syncytial virus F and G proteins.Combination therapy using monoclonal antibodies against respiratory syncytial virus (RSV) G glycoprotein protects from RSV disease in BALB/c mice.Full-length and truncated neurokinin-1 receptor expression and function during monocyte/macrophage differentiation.Nanoparticle vaccines encompassing the respiratory syncytial virus (RSV) G protein CX3C chemokine motif induce robust immunity protecting from challenge and disease.Decrease in formalin-inactivated respiratory syncytial virus (FI-RSV) enhanced disease with RSV G glycoprotein peptide immunization in BALB/c mice.Development of safe and effective RSV vaccine by modified CD4 epitope in G protein core fragment (Gcf).An anti-G protein monoclonal antibody treats RSV disease more effectively than an anti-F monoclonal antibody in BALB/c mice.Antibodies to the central conserved region of respiratory syncytial virus (RSV) G protein block RSV G protein CX3C-CX3CR1 binding and cross-neutralize RSV A and B strains.Novel antigens for RSV vaccines.Seasonal Timing of Infant Bronchiolitis, Apnea and Sudden Unexplained Infant DeathCX3CR1 is an important surface molecule for respiratory syncytial virus infection in human airway epithelial cells.Cotton rat immune responses to virus-like particles containing the pre-fusion form of respiratory syncytial virus fusion protein.Layer-By-Layer Nanoparticle Vaccines Carrying the G Protein CX3C Motif Protect against RSV Infection and DiseaseCharacterization of recombinant respiratory syncytial viruses with the region responsible for type 2 T-cell responses and pulmonary eosinophilia deleted from the attachment (G) protein.Human genetic factors and respiratory syncytial virus disease severity.RNA interference inhibits respiratory syncytial virus replication and disease pathogenesis without inhibiting priming of the memory immune response.Pulmonary immunity and immunopathology: lessons from respiratory syncytial virus.A respiratory syncytial virus (RSV) anti-G protein F(ab')2 monoclonal antibody suppresses mucous production and breathing effort in RSV rA2-line19F-infected BALB/c mice.Th17 cytokines are critical for respiratory syncytial virus-associated airway hyperreponsiveness through regulation by complement C3a and tachykinins.Understanding respiratory syncytial virus (RSV) vaccine development and aspects of disease pathogenesis.The Central Conserved Region (CCR) of Respiratory Syncytial Virus (RSV) G Protein Modulates Host miRNA Expression and Alters the Cellular Response to Infection.Roles of Non-coding RNAs in Respiratory Syncytial Virus (RSV) Infection.Respiratory syncytial virus F and G proteins induce interleukin 1alpha, CC, and CXC chemokine responses by normal human bronchoepithelial cells.Distinct patterns of innate immune activation by clinical isolates of respiratory syncytial virus.Mutating the CX3C Motif in the G Protein Should Make a Live Respiratory Syncytial Virus Vaccine Safer and More Effective.Human Respiratory Syncytial Virus: An Introduction.A Recombinant G Protein Plus Cyclosporine A-Based Respiratory Syncytial Virus Vaccine Elicits Humoral and Regulatory T Cell Responses against Infection without Vaccine-Enhanced Disease.Respiratory syncytial virus G protein CX3C motif impairs human airway epithelial and immune cell responses.Expression of chemokine receptor CX3CR1 in infants with respiratory syncytial virus bronchiolitis.In Vivo Assessment of Airway Function in the Mouse Model.
P2860
Q26823449-8ECA7D06-8ED9-434F-BC59-116927F811FFQ27022693-0F44F96B-330F-49E9-A02E-F6B9AE3F38F2Q33302897-A8B05560-4E5D-42E3-A61F-AEA8B7D1DE7CQ33558356-C478E594-414F-4A30-B857-D082FB74D5C1Q33881536-AE396D61-59DE-469B-AE2F-EA3BF1855750Q34120278-348F325E-D3B5-49F5-BBC7-514175B9DAD0Q34222406-64913882-9ABC-4966-9958-FF244BE2E34AQ34262180-B52FA015-4A1C-4363-81C8-BF54D79A1C23Q34457791-D42FDC1A-BF32-41E9-92BC-1E1EB0C91255Q34540179-339776BD-4EB8-4C0D-A16C-61A3C3311EC7Q34591209-93F0F5D1-8EEB-45DF-8ECE-99AD041FA706Q34990420-AA42BF20-692E-44A3-9D6B-9512B3DDC6BEQ35077892-C15124A1-33C7-4409-8A9E-D789AB636217Q35149594-97314831-FBCC-4601-AD47-4F8749A795CEQ35893983-30261A45-C63E-42EB-9E69-A33D0E631C87Q36005114-9041088A-D036-4301-81E1-23B80C3A5198Q36005960-4F151F58-D35E-4E4D-8DFD-FC2893A871AAQ36073885-DE8AB457-6BCC-4DD5-A18C-22F4B0ECF606Q36255118-321C24B3-BA17-4DC3-B326-D0B38A26965CQ36256989-855379EC-9F33-4A00-A89F-232156C25C0DQ36409517-0D242002-C196-4D46-9126-20D87FFE7CECQ36684360-7CCBE40A-EDAE-416B-B043-D94D27F1D722Q36943137-7C118F62-A390-4B4C-B79F-C828A304A099Q36994716-2A306EF7-985C-4563-94C6-C7DEF07D886BQ37071608-2416C00A-51E2-409A-8FB6-6423A67B76D3Q37252613-B15C24A3-0EE4-477D-A727-DDFF0C11DF4BQ38625810-CCA937CC-57F5-4573-866B-7642EC040385Q38660842-E46A335E-FB12-4656-AC36-CA089957BAEEQ38696909-53E303C3-F752-4CD8-96B8-5ADB9DB4C991Q39395437-7C44E332-F419-4495-A803-2E094F69A4B3Q39635571-B7D4FD80-97D0-4C2E-B44A-E965C5AA1703Q40055725-6B84C464-0BF1-41AB-91F9-B6384873E2A2Q40301155-9022BEC5-46E2-47B5-9C17-9AC94A096146Q40597806-92791A30-0BD2-443C-B9FD-568D6C06F42BQ40823850-6F0C715D-DC97-4BD3-A9B6-902400F03732Q41838015-6CAD2AD0-41C3-4ABC-8346-F74263B3392BQ45397301-45986B85-7A16-4DB1-AA1B-04D0EA0614C6Q47404771-D16C8A15-3DE1-4D0A-B8F3-BC885A3DAEC4
P2860
The G glycoprotein of respiratory syncytial virus depresses respiratory rates through the CX3C motif and substance P.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
The G glycoprotein of respirat ...... he CX3C motif and substance P.
@ast
The G glycoprotein of respirat ...... he CX3C motif and substance P.
@en
The G glycoprotein of respirat ...... he CX3C motif and substance P.
@nl
type
label
The G glycoprotein of respirat ...... he CX3C motif and substance P.
@ast
The G glycoprotein of respirat ...... he CX3C motif and substance P.
@en
The G glycoprotein of respirat ...... he CX3C motif and substance P.
@nl
prefLabel
The G glycoprotein of respirat ...... he CX3C motif and substance P.
@ast
The G glycoprotein of respirat ...... he CX3C motif and substance P.
@en
The G glycoprotein of respirat ...... he CX3C motif and substance P.
@nl
P2093
P2860
P50
P1433
P1476
The G glycoprotein of respirat ...... the CX3C motif and substance P
@en
P2093
Albert Barskey
Larry J Anderson
Les P Jones
P2860
P304
P356
10.1128/JVI.77.11.6580-6584.2003
P407
P577
2003-06-01T00:00:00Z